etoposide has been researched along with hydroxychloroquine in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Bialy-Golan, A; Brenner, S; Gat, A; Golan, H | 1 |
Feller, JM; Fraser, MJ; Meng, XW; Ziegler, JB | 1 |
Junga, Z; Keith, M; Stitt, R; Tracy, C | 1 |
Angelov, D; Cotter, AG; Fay, M; Lambert, JS; McGettrick, P; McGinty, T; O'Kelly, B; Sheehan, G | 1 |
2 review(s) available for etoposide and hydroxychloroquine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Dermatologic Agents; Doxorubicin; Etoposide; Female; Humans; Hydroxychloroquine; Lung Neoplasms; Lupus Erythematosus, Cutaneous; Middle Aged; Paraneoplastic Syndromes | 1997 |
4 other study(ies) available for etoposide and hydroxychloroquine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Caspase-3-dependent and caspase-3-independent pathways leading to chromatin DNA fragmentation in HL-60 cells.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Aurintricarboxylic Acid; Caspase 3; Caspase Inhibitors; Caspases; Cell Nucleus; Chromatin; DNA Fragmentation; Etoposide; HL-60 Cells; Humans; Hydroxychloroquine; Oligopeptides; Proteins; Subcellular Fractions | 2000 |
Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
Topics: Antineoplastic Agents, Immunological; Antirheumatic Agents; Diagnosis, Differential; Etoposide; Female; Humans; Hydroxychloroquine; Infusions, Intravenous; Lupus Erythematosus, Systemic; Macrophage Activation Syndrome; Rare Diseases; Rituximab; Treatment Outcome; Young Adult | 2017 |
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Bleomycin; Coronavirus Infections; COVID-19; Cyclophosphamide; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Hydroxychloroquine; Idarubicin; Mediastinal Neoplasms; Pandemics; Pneumonia, Viral; Positron-Emission Tomography; Prednisone; Procarbazine; SARS-CoV-2; Treatment Outcome; Vinblastine; Vincristine | 2020 |